Inflammatix: Raises $32M in Series C Funding
- Inflammatix raises $32M, plus a BARDA contract, for its point-of-care infection diagnostics
- The company also intends to use the funds to advance its rapid HostDx™ tests through commercial launch in Europe and US
- Inflammatix’s tests also use machine learning algorithms to parse the expression of multiple immune system genes
- It designed to produce point-of-care results in 30 minutes or less
- Then the company said it plans to submit its tests for FDA review in 2021
- The Series C funding comes on the heels of the Burlingame, California-based firm inking a long-term, cost-sharing contract in November 2019
